Q: What is Sogroya used for?

Sogroya is used to treat adult growth hormone deficiency .

Q: How does Sogroya work?

Mechanism of Action Sogroya (somapacitan-beco) is a recombinant human growth hormone. It works by mimicking the actions of the natural growth hormone produced by the pituitary gland. When the medication is injected, it travels through the body and attaches to growth hormone receptors on the surface of target cells. This attachment triggers a series of signals inside the cells that lead to several important biological effects: Tissue Growth: It promotes the growth of bones and muscles, which is particularly important for children who are not growing at a typical rate. Hormone Production: It stimulates the liver and other tissues to release insulin-like growth factor 1 (IGF-1), a hormone that further supports growth and development. Metabolic Support: It helps regulate the way the body processes and uses proteins, fats, and sugars. Weekly Dosing Technology The primary difference between Sogroya and traditional growth hormone treatments is how long it stays active in the body. Sogroya is modified to bind to albumin, a protein naturally found in the blood. This binding protects the medication from being quickly cleared out by the kidneys or broken down by the body. Because it circulates in the bloodstream for an extended period, it only needs to be injected once a week to maintain effective levels.

Q: What are the active ingredients in Sogroya?

The active ingredient in Sogroya is somapacitan .

Q: What are the side effects of Sogroya?

Common side effects of Sogroya may include: Headache Joint pain Injection site reactions Always consult with a healthcare professional about potential side effects.

Q: What drug class is Sogroya?

Sogroya belongs to the growth hormone receptor agonist drug class.

Q: What is the dosage of Sogroya and how do I take it?

How to Use Sogroya is given as a subcutaneous injection, which means it is injected into the fatty tissue just under the skin. It is typically administered once a week, on the same day each week, at any time of day. A healthcare provider will demonstrate how to use the prefilled pen and how to prepare the injection. Injection Sites The medication should be injected into the abdomen, thighs, buttocks, or upper arms. It is important to rotate the injection site with every dose to reduce the risk of skin problems. Avoid injecting into skin that is tender, bruised, red, or hard, and stay away from areas with scars or stretch marks. Missed Dose If a dose is missed, it should be administered as soon as possible if it is within 3 days of the scheduled day. If more than 3 days have passed since the dose was supposed to be taken, skip the missed dose and wait until the next regularly scheduled day to take the next dose. Do not use two doses at once to make up for a missed one.

Q: Is Sogroya safe during pregnancy and breastfeeding?

Pregnancy There is not enough research on the use of Sogroya in pregnant women to determine if it causes birth defects, miscarriage, or other developmental issues. In animal studies, some fetal abnormalities were observed when the medication was given at doses much higher than the standard human dose. Because of the lack of human data, healthcare providers typically only recommend Sogroya during pregnancy if the potential benefit to the patient outweighs the potential risk to the unborn baby. Breastfeeding It is not known whether Sogroya passes into human breast milk, how it might affect a nursing infant, or if it impacts the production of milk. Because many medications can be passed through breast milk, it is important to discuss the potential risks and benefits with a healthcare professional if you are breastfeeding or planning to breastfeed while using this medication.

Q: What forms and strengths does Sogroya come in?

Available Forms Sogroya is supplied as a clear and colorless solution for injection. It is administered subcutaneously, which means it is injected into the fatty tissue just beneath the skin. The medication is provided in the following delivery system: Pre-filled Pen: A disposable, single-patient-use injection device. The pen is designed to be used with compatible disposable needles. It features a dose-setting mechanism that allows the user to select the prescribed amount of medication for each injection.

Q: What is the FDA approval status of Sogroya?

FDA Approval History The U.S. Food and Drug Administration (FDA) initially approved Sogroya (somapacitan-beco) in August 2020. It was the first once-weekly human growth hormone (hGH) therapy approved for adults with growth hormone deficiency. In April 2023, the FDA expanded the approval to include the treatment of pediatric patients 2.5 years of age and older who have growth failure due to inadequate secretion of endogenous growth hormone. Regulatory Oversight Sogroya is a prescription-only medication. There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategy (REMS) requirements associated with its use. The FDA-approved labeling includes warnings regarding potential risks common to the growth hormone class, such as: Increased mortality in patients with acute critical illness Risk of progression or recurrence of tumors Glucose intolerance and diabetes mellitus Intracranial hypertension Fluid retention Healthcare providers are advised to monitor patients regularly for these conditions and adjust treatment as necessary based on clinical response and laboratory testing of insulin-like growth factor-1 (IGF-1) levels.

Question 1

What is Sogroya?

Accepted Answer

Sogroya is a recombinant human growth hormone analog. It functions by binding to growth hormone receptors, mimicking the effects of the growth hormone naturally produced by the pituitary gland.

This medication plays a role in regulating various metabolic processes and supporting physical development. As a long-acting formulation, it is designed to maintain growth hormone levels over an extended period.

Question 2

What is Sogroya used for?

Accepted Answer

Sogroya is used to treat adult growth hormone deficiency.

Question 3

How does Sogroya work?

Accepted Answer

Mechanism of Action

Sogroya (somapacitan-beco) is a recombinant human growth hormone. It works by mimicking the actions of the natural growth hormone produced by the pituitary gland. When the medication is injected, it travels through the body and attaches to growth hormone receptors on the surface of target cells.

This attachment triggers a series of signals inside the cells that lead to several important biological effects:

Tissue Growth: It promotes the growth of bones and muscles, which is particularly important for children who are not growing at a typical rate.
Hormone Production: It stimulates the liver and other tissues to release insulin-like growth factor 1 (IGF-1), a hormone that further supports growth and development.
Metabolic Support: It helps regulate the way the body processes and uses proteins, fats, and sugars.

Weekly Dosing Technology

The primary difference between Sogroya and traditional growth hormone treatments is how long it stays active in the body. Sogroya is modified to bind to albumin, a protein naturally found in the blood. This binding protects the medication from being quickly cleared out by the kidneys or broken down by the body. Because it circulates in the bloodstream for an extended period, it only needs to be injected once a week to maintain effective levels.

Question 4

What are the active ingredients in Sogroya?

Accepted Answer

The active ingredient in Sogroya is somapacitan.

Question 5

What are the side effects of Sogroya?

Accepted Answer

Common side effects of Sogroya may include:

Headache
Joint pain
Injection site reactions

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Sogroya?

Accepted Answer

Sogroya belongs to the growth hormone receptor agonist drug class.

Question 7

What is the dosage of Sogroya and how do I take it?

Accepted Answer

How to Use

Sogroya is given as a subcutaneous injection, which means it is injected into the fatty tissue just under the skin. It is typically administered once a week, on the same day each week, at any time of day. A healthcare provider will demonstrate how to use the prefilled pen and how to prepare the injection.

Injection Sites

The medication should be injected into the abdomen, thighs, buttocks, or upper arms. It is important to rotate the injection site with every dose to reduce the risk of skin problems. Avoid injecting into skin that is tender, bruised, red, or hard, and stay away from areas with scars or stretch marks.

Missed Dose

If a dose is missed, it should be administered as soon as possible if it is within 3 days of the scheduled day. If more than 3 days have passed since the dose was supposed to be taken, skip the missed dose and wait until the next regularly scheduled day to take the next dose. Do not use two doses at once to make up for a missed one.

Question 8

Is Sogroya safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There is not enough research on the use of Sogroya in pregnant women to determine if it causes birth defects, miscarriage, or other developmental issues. In animal studies, some fetal abnormalities were observed when the medication was given at doses much higher than the standard human dose. Because of the lack of human data, healthcare providers typically only recommend Sogroya during pregnancy if the potential benefit to the patient outweighs the potential risk to the unborn baby.

Breastfeeding

It is not known whether Sogroya passes into human breast milk, how it might affect a nursing infant, or if it impacts the production of milk. Because many medications can be passed through breast milk, it is important to discuss the potential risks and benefits with a healthcare professional if you are breastfeeding or planning to breastfeed while using this medication.

Question 9

What forms and strengths does Sogroya come in?

Accepted Answer

Available Forms

Sogroya is supplied as a clear and colorless solution for injection. It is administered subcutaneously, which means it is injected into the fatty tissue just beneath the skin.

The medication is provided in the following delivery system:

Pre-filled Pen: A disposable, single-patient-use injection device.

The pen is designed to be used with compatible disposable needles. It features a dose-setting mechanism that allows the user to select the prescribed amount of medication for each injection.

Question 10

What is the FDA approval status of Sogroya?

Accepted Answer

FDA Approval History

The U.S. Food and Drug Administration (FDA) initially approved Sogroya (somapacitan-beco) in August 2020. It was the first once-weekly human growth hormone (hGH) therapy approved for adults with growth hormone deficiency. In April 2023, the FDA expanded the approval to include the treatment of pediatric patients 2.5 years of age and older who have growth failure due to inadequate secretion of endogenous growth hormone.

Regulatory Oversight

Sogroya is a prescription-only medication. There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategy (REMS) requirements associated with its use. The FDA-approved labeling includes warnings regarding potential risks common to the growth hormone class, such as:

Increased mortality in patients with acute critical illness
Risk of progression or recurrence of tumors
Glucose intolerance and diabetes mellitus
Intracranial hypertension
Fluid retention

Healthcare providers are advised to monitor patients regularly for these conditions and adjust treatment as necessary based on clinical response and laboratory testing of insulin-like growth factor-1 (IGF-1) levels.

Question 11

What should I know about Sogroya and cost?

Accepted Answer

Insurance and Coverage

The out-of-pocket cost for Sogroya is largely determined by your health insurance plan. Many insurance providers require prior authorization for this medication. This process involves your healthcare provider submitting documentation to the insurance company to confirm that the treatment is medically necessary before coverage is approved.

Specialty Pharmacies

Sogroya is a specialty medication and is typically dispensed through specialty pharmacies rather than standard retail pharmacies. These pharmacies are equipped to handle injectable growth hormones and can often assist with navigating insurance benefits and coordinating delivery.

Financial Assistance

Programs may be available to help reduce the cost of Sogroya for eligible patients. These options often include:

Copay Savings Cards: These may be available for patients with commercial or private insurance to help lower their monthly out-of-pocket expenses.
Patient Assistance Programs: Some programs provide the medication at a lower cost or for free to individuals who meet specific income requirements or who do not have insurance coverage.

Because prices can vary significantly based on the pharmacy and your specific insurance tier, it is recommended to contact your insurance provider or the manufacturer's support services for the most accurate cost information.

Sogroya

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Sogroya

Hospitals.net Disclosure